DaVita Announces $750M Senior Notes Offering

DaVita ( (DVA) ) has issued an announcement.

On May 20, 2025, DaVita Inc. announced the initiation of a private offering of $750 million in senior notes due in 2033, with proceeds intended to repay existing credit facilities and cover associated costs, with any remaining funds allocated for general corporate purposes. This strategic financial move is designed to strengthen DaVita’s financial position, potentially impacting its operations and industry standing, while also reflecting its ongoing commitment to financial flexibility and growth.

The most recent analyst rating on (DVA) stock is a Sell with a $145.00 price target. To see the full list of analyst forecasts on DaVita stock, see the DVA Stock Forecast page.

Spark’s Take on DVA Stock

According to Spark, TipRanks’ AI Analyst, DVA is a Neutral.

DaVita’s overall score is driven by strong financial management and effective handling of operational challenges, such as a cybersecurity incident. The company’s high leverage and negative equity are significant risks, but these are partially offset by robust cash flow and strategic capital allocation. While technical indicators show some bearish sentiment, the valuation remains reasonable. Positive earnings call insights and maintained guidance further bolster the outlook.

To see Spark’s full report on DVA stock, click here.

More about DaVita

DaVita (NYSE: DVA) is a healthcare provider specializing in comprehensive kidney care, aiming to enhance patients’ quality of life globally. The company is recognized for its leadership in clinical quality and innovation over the past 25 years, offering services from slowing kidney disease progression to supporting transplantation and providing both acute hospital care and home dialysis.

Average Trading Volume: 926,813

Technical Sentiment Signal: Buy

Current Market Cap: $10.94B

See more insights into DVA stock on TipRanks’ Stock Analysis page.